- Scrip Awards 2013 Licensing Deal of the Year
Awarded to AstraZeneca and Horizon Discovery for the development and commercialization of the HD-001 kinase target program for multiple cancer types.
HD-001 case study can be found here: www.horizondiscovery.com/media/item/67
- Deloitte UK Technology Fast 50
Horizon took position 22 on the list. The Deloitte Technology Fast 50 is one of the UK's foremost technology award programs. It is a ranking of the country's 50 fastest growing technology companies, based on revenue growth over the last five years. - Tech City Future Fifty program
The program is designed to help high-growth businesses accelerate their growth and lay the foundations for their next major liquidity event. As part of the scheme, Horizon will have access to a program of tailored support from both the public and private sector. - 125 most influential Cambridge businesses
To mark Cambridge News’ 125th anniversary, a panel of judges pinpointed the companies and other organizations that have been most influential in shaping the region’s economy.
More to be announced in December.
Earlier this year Horizon announced the licensing of key IP for both CRISPR and zinc finger nuclease (ZFN) technologies, adding to its GENESIS™ precision gene-editing platform. With these additions, Horizon holds a unique position among translational genomics companies by offering access to and expertise in all three genome editing technologies (CRISPR, ZFN, rAAV). Horizon offers researchers an unrivalled toolbox capable of performing rapid functional genomics experiments, as well as creation of high-precision human disease models for deployment at all stages of drug discovery and diagnostic development.
About Horizon Discovery www.horizondiscovery.com/
Horizon Discovery Limited (Horizon) is a leading provider of research tools to support translational genomics research and the development of personalized medicines. Using GENESISTM, Horizon is able to alter any endogenous gene sequence of a human or mammalian cell-line quickly, reliably and without introducing unwanted and confounding genotypes and/or phenotypes.
Horizon has applied GENESIS to create over 500 X-MAN™ cell lines, the world’s first source of genetically-defined and patient-relevant human cell lines, accurately modeling the disease-causing mutations found in cancer patients. These ‘patients-in-a-test-tube’ are being used by academic and industry leaders to identify the effect of individual or compound genetic mutations on drug activity, patient responsiveness, and resistance, leading to the successful prediction of which patient sub-groups will respond to currently-available and future drug treatments. This enables the design of shorter, more focused, and less expensive clinical trials, ultimately providing the tools to identify the ‘right drugs’ for the ‘right patients’ based upon the unique genetic mutations that define their disease.
In addition to the X-MAN cell lines, Horizon provides GENESIS and X-MAN™ derived products and services, with industrial application in: bio-pharmaceutical process optimization; clinical diagnostic development; drug discovery & development; and the provision of reference standards for genomic-based clinical research platforms.
*******
Contacts:
At Horizon:
Chris Claxton
Email: c.claxton@horizondiscovery.com
Media enquiries for Horizon:
Katie Odgaard
Zyme Communications
Tel: +44 (0)7787 502 948
Email: katie.odgaard@zymecommunications.com
________________________________________________________